Send To Friend
Set As Home Page
Quick Search
 Quick Search
0 items|0.00 $
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Join our Newsletter
Enter E-mail Here
 
Popular Products
Interleukins
Interferons
BMPs
TNFs
CSFs
SCFs
VEGFs
FGFs
PDGFs
IGFs
Leptins
Prolactins
Growth Hormones
SDFs
MCPs
MIPs
GROs
Products catalog >> Enzymes >> sPLA2 >> PLA2 V Human

PLA2 V Human
Secreted Phospholipase A2-V Human Recombinant

Catalog No. ENZ-328
Options:
Size/Price :
Quantity :

Synonyms:
Calcium-dependent phospholipase A2, EC
3.1.1.4, Phosphatidylcholine 2-acylhydrolase, PLA2-10, Group V phospholipase A2, GV-PLA2, MGC46205, hVPLA(2), DKFZp686C2294, sPLA2-V.

Introduction:
Phospholipase A2 (PLA2) catalyzes the hydrolysis of the sn-2 position of membrane glycerophospholipids to liberate arachidonic acid (AA), a precursor of eicosanoids including prostaglandins and leukotrienes. The same reaction also produces lysophosholipids, which represent another class of lipid mediators.
The secretory PLA2 (sPLA2) family, in which 10 isozymes have been identified, consists of low molecular weight, Ca2+-requiring secretory enzymes that have been implicated in a number of biological processes, such as modification of eicosanoid generation, inflammation, and host defense.
This enzyme has been proposed to hydrolyze phosphatidylcholine (PC) in lipoproteins to liberate lyso-PC and free fatty acids in the arterial wall, thereby facilitating the accumulation of bioactive lipids and modified lipoproteins in atherosclerotic foci.
In mice, sPLA2 expression significantly influences HDL particle size and composition and demonstrate that an induction of sPLA2 is required for the decrease in plasma HDL cholesterol in response to inflammatory stimuli. Instillation of bacteria into the bronchi was associated with surfactant degradation and a decrease in large:small ratio of surfactant aggregates in rats.

 Description:
Secreted Phospholipase A2-V Human Recombinant was produced with N-terminal His-Tag. sPLA2-VHis-Tagged Fusion protein is 15.5 kDa containing 118 amino acid residues of the human secreted phospholipase A2-V and 16 additional amino acid residues – His-Tag (underlined).
MRGSHHHHHH GMASHMGLLD LKSMIEKVTG KNALTNYGFY GCYCGWGGRG TPKDGTDWCC WAHDHCYGRLEEKGCNIRTQ SYKYRFAWGV VTCEPGPFCH VNLCACDRKL VYCLKRNLRS YNPQYQYFPN ILCS

 Source:
Escherichia Coli.

Physical Appearance
:
Sterile Filtered lyophilized (freeze-dried) powder.

Formulation:
Sterile filtered and lyophilized from 0.5 mg/ml in 0.05M Acetate buffer pH-4.

Reconstitution:
Add 0.2 ml of 0.1M Acetate buffer pH-4 and let the lyophilized pellet dissolve completely. For conversion into higher pH value, we recommend intensive dilution by relevant buffer to a concentration of 10 μg/ml. In higher concentrations the solubility of this antigen is limited.

Storage:
Store lyophilized protein at -20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles. Reconstituted protein can be stored at 4°C for a limited period of time; it does not show any change after two weeks at 4°C.
The lyophilized protein remains stable until the expiry date when stored at -20°C.

Specificity:
The amino acid sequence of the recombinant human Secreted Phospholipase A2-V is 100% homologous to the amino acid sequence of the human Secreted Phospholipase A2-V without signal sequence.

Purification Method:
Ni-NTA affinity chromatography

Purity:
Greater than 95% as determined by SDS PAGE.

Applications:
Western blotting

References:
• Murakami M, Kudo I. New phospholipase A(2) isozymes with a potential role in atherosclerosis. Curr Opin Lipidol. 2003 Oct; 14(5): 431-6.
• Touqui L, Alaoui-El-Azher M. Mammalian secreted phospholipases A2 and their pathophysiological significance in inflammatory diseases. Curr Mol Med. 2001 Dec; 1(6): 739-54. Review.
• Ito M, Ishikawa Y, Kiguchi H, Komiyama K, Murakami M, Kudo I, Akasaka Y, Ishii T. Distribution of type V secretory phospholipase A2 expression in human hepatocytes damaged by liver disease. J Gastroenterol Hepatol. 2004 Oct;19(10):1140-9.
• Wooton-Kee CR, Boyanovsky BB, Nasser MS, de Villiers WJ, Webb NR. Group V sPLA2 hydrolysis of low-density lipoprotein results in spontaneous particle aggregation and promotes macrophage foam cell formation. Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):762-7.
• Satake Y, Diaz BL, Balestrieri B, Lam BK, Kanaoka Y, Grusby MJ, Arm JP. Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J Biol Chem. 2004 Apr 16;279(16):16488-94.
• Balboa MA, Shirai Y, Gaietta G, Ellisman MH, Balsinde J, Dennis EA. Localization of group V phospholipase A2 in caveolin-enriched granules in activated P388D1 macrophage-like cells. J Biol Chem. 2003 Nov 28;278(48):48059-65.

Usage:
Prospec's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.

print Accession #
send to friend add to favorites
Related Products
» PLA2 IB Human
» PLA2 IIA Human
» PLA2 IID Human
» PLA2 IIE Human
» PLA2 X Human
» PLA2 XII Human
Advance Products Search
Search
News
New Products 2008 (click to view)
Cytokines
Chemokines
Hormones
Viral Antigens
Enzymes

Download
our 2008 Catalogue

USA Toll Free Phone: 866-245-0885
USA Toll Free Fax: 866-796-4944

Europe Toll Free Phone: 00-800-800-66666
Europe Toll Free Fax: 00-800-800-67890

International Phone: +972-8-9471175
International Fax: +972-8-9460534

www.prospecbio.com
info@prospecbio.com

Rehovot Science Park, Po. Box
398 Rehovot 76103, Israel

  Home | Legal | Privacy | Site Map | Cytokines | Growth Factors | Chemokines | CD Antigens | Neurotrophins | Hormones | Enzymes | Recombinant Proteins | Viral Antigens | Monoclonal Antibodies